NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 25 04:00PM ET
7.76
Dollar change
-0.29
Percentage change
-3.60
%
Index- P/E- EPS (ttm)-19.54 Insider Own9.21% Shs Outstand3.38M Perf Week6.59%
Market Cap27.32M Forward P/E- EPS next Y-15.76 Insider Trans0.00% Shs Float3.20M Perf Month-25.50%
Income-41.84M PEG- EPS next Q-3.29 Inst Own6.21% Short Float3.44% Perf Quarter-37.17%
Sales0.00M P/S- EPS this Y29.93% Inst Trans- Short Ratio1.76 Perf Half Y-43.15%
Book/sh5.65 P/B1.37 EPS next Y-15.32% ROA-87.51% Short Interest0.11M Perf Year-82.55%
Cash/sh8.60 P/C0.90 EPS next 5Y11.82% ROE-182.35% 52W Range5.35 - 49.27 Perf YTD-28.47%
Dividend Est.- P/FCF- EPS past 5Y50.16% ROI-153.45% 52W High-84.25% Beta-1.73
Dividend TTM- Quick Ratio2.21 Sales past 5Y0.00% Gross Margin- 52W Low45.06% ATR (14)0.78
Dividend Ex-Date- Current Ratio2.21 EPS Y/Y TTM-220.54% Oper. Margin- RSI (14)44.51 Volatility6.91% 12.31%
Employees25 Debt/Eq0.80 Sales Y/Y TTM- Profit Margin- Recom2.33 Target Price94.00
Option/ShortNo / Yes LT Debt/Eq0.43 EPS Q/Q9.72% Payout- Rel Volume0.42 Prev Close8.05
Sales Surprise- EPS Surprise-23.08% Sales Q/Q- EarningsMar 27 AMC Avg Volume62.44K Price7.76
SMA20-0.37% SMA50-19.64% SMA200-44.35% Trades Volume26,339 Change-3.60%
Date Action Analyst Rating Change Price Target Change
Apr-10-25Downgrade Scotiabank Sector Outperform → Sector Perform
Apr-10-25Downgrade H.C. Wainwright Buy → Neutral
Mar-14-24Initiated Scotiabank Sector Outperform $13
Feb-08-24Initiated Jefferies Buy $15
Apr-21-25 08:00AM
Apr-10-25 11:05AM
Apr-09-25 04:30PM
Mar-27-25 04:10PM
Mar-25-25 04:30PM
08:00AM Loading…
Mar-13-25 08:00AM
Feb-10-25 08:00AM
Feb-07-25 04:30PM
Jan-06-25 08:00AM
Dec-06-24 04:30PM
Dec-05-24 09:00PM
Nov-25-24 04:30PM
Nov-12-24 04:21PM
08:00AM
Oct-10-24 07:01AM
07:00AM Loading…
07:00AM
Sep-20-24 04:30PM
Sep-18-24 08:00AM
Sep-05-24 08:00AM
Aug-23-24 04:30PM
Aug-21-24 08:00AM
Aug-15-24 08:00AM
Aug-08-24 04:56PM
Jun-20-24 08:13AM
08:00AM
07:28AM
Jun-18-24 06:22PM
Jun-07-24 04:30AM
May-21-24 08:00AM
May-09-24 04:29PM
04:05PM Loading…
Apr-26-24 04:05PM
Apr-09-24 08:00AM
Apr-04-24 08:00AM
Mar-19-24 09:53PM
04:25PM
Mar-12-24 08:00AM
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-02-24 04:30PM
Jan-05-24 04:05PM
Dec-01-23 04:15PM
Nov-20-23 08:00AM
Nov-08-23 05:17PM
Oct-12-23 08:25AM
Oct-11-23 04:29PM
08:01AM
08:00AM
07:41AM
Oct-10-23 04:05PM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-10-23 04:13PM
Jul-19-23 08:00AM
May-31-23 04:05PM
May-25-23 05:00PM
May-19-23 04:05PM
May-10-23 04:15PM
Apr-28-23 08:00AM
Apr-27-23 04:58PM
Apr-26-23 06:41PM
Apr-17-23 09:00AM
Mar-22-23 05:26PM
Mar-15-23 04:05PM
Mar-14-23 04:30PM
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
08:00AM
Apr-08-22 01:00PM
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Versant Venture Capital VI, L.OwnerAug 12 '24Proposed Sale1.10387,999426,993Aug 13 08:03 AM
Versant Venture Capital VI, L.10% OwnerAug 08 '24Sale1.35400,000540,040597,940Aug 12 08:33 PM
Versant Venture Capital VI, L.10% OwnerAug 12 '24Sale1.10387,999426,993209,941Aug 12 08:33 PM
Versant Venture Capital VI, L.10% OwnerAug 08 '24Proposed Sale18.03400,0007,210,532Aug 09 03:41 PM
Brady Stephen RPresident and CEOJul 03 '24Buy2.1135,00073,85046,376Jul 08 04:15 PM
Whiting SamuelChief Medical OfficerJul 02 '24Buy2.134,6729,9519,573Jul 03 07:35 PM
Trojanowski JustinCorporate ControllerJun 28 '24Buy2.167,50016,20022,168Jul 02 04:15 PM